| Name | Title | Contact Details |
|---|
Novarix is a collaborative medical device development company based near Oxford, UK and Raleigh, North Carolina, USA, delivering innovative new products in the field of venepuncture and cannulation to the worldwide healthcare sector. Novarix are proud to bring to market the IV-eye® – a portable, near infrared (NIR) vein imaging device which demonstrates the company ethos of practicality, simplicity and performance for both healthcare professionals and patients. The product idea came from a nursing perspective and has been developed in consultation with medical professionals in the UK and Denmark and with assistance from the biomedical engineering departments of Oxford University and University College London.
Quantel Medical is a Bozeman, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pelikan Technologies is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
bioTheranostics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.